Disturbed trophoblast transition links early fetal to maternal syndrome progression in pre-eclampsia
- Nonn, Olivia1
- Debnath, Olivia2
- Valdes, Daniela S.3
- Sallinger, Katja4
- Secener, Kerim5
- Haider, Sandra6
- Fischer, Cornelius7
- Tiesmeyer, Sebastian2
- Nimo, Jose8
- Kuenzer, Thomas9
- Maxian, Theresa10
- Knöfler, Martin10
- Karau, Philipp2
- Bartolomaeus, Hendrik11
- Kroneis, Thomas4
- Frolova, Alina12
- Neuper, Lena13
- Haase, Nadine14
- Kräker, Kristin15
- Kedziora, Sarah15
- Forstner, Désirée16
- Verlohren, Stefan17
- Stern, Christina18
- Cosica, Fabian8
- Sugulle, Meryam19
- Jones, Stuart20
- Tilaganathan, Basky21
- Eils, Roland2
- Huppertz, Berthold16
- El-Heliebi, Amin4
- Staff, Anne Cathrine19
- Müller, Dominik N.15
- Dechend, Ralf22
- Gauster, Martin16
- Ishaque, Naveed2
- Herse, Florian3
- 1. Division of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Medical University of Graz, Graz, Austria; Experimental and Clinical Research Center, a cooperation between the Max‐Delbrück‐Center for Molecular Medicine in the Helmholtz Association and the Charité ‐ Universitätsmedizin Berlin, Berlin, Germany; Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt‐Universität zu Berlin, Berlin, Germany; Max‐Delbrück‐Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
- 2. Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Digital Health Center, Berlin, Germany
- 3. Experimental and Clinical Research Center, a cooperation between the Max‐Delbrück‐Center for Molecular Medicine in the Helmholtz Association and the Charité ‐ Universitätsmedizin Berlin, Berlin, Germany; Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt‐Universität zu Berlin, Berlin, Germany; Max‐Delbrück‐Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
- 4. Division of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Medical University of Graz, Graz, Austria; Centre for Biomarker Research in Medicine (CBmed), Graz, Austria
- 5. Institute for Medical Systems Biology (BIMSB), Berlin, Germany; Institute of Chemistry and Biochemistry, Department of Biology, Chemistry and Pharmacy, Freie Universität Berlin, Germany
- 6. Department of Obstetrics and Gynaecology, Reproductive Biology Unit, Medical University of Vienna, Vienna, Austria
- 7. Institute for Medical Systems Biology (BIMSB), Berlin, Germany
- 8. Max‐Delbrück‐Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
- 9. Institute of Statistics, University of Technology Graz, Austria
- 10. Department of Obstetrics and Gynaecology, Reproductive Biology Unit, Medical University of Vienna, Austria
- 11. Experimental and Clinical Research Center, a cooperation between the Max‐Delbrück‐Center for Molecular Medicine in the Helmholtz Association and the Charité ‐ Universitätsmedizin Berlin, Germany
- 12. Institute of Molecular Biology and Genetic of NASU, Kyiv, Ukraine
- 13. Division of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Medical University of Graz, Austria
- 14. Experimental and Clinical Research Center, a cooperation between the Max‐Delbrück‐Center for Molecular Medicine in the Helmholtz Association and the Charité ‐ Universitätsmedizin Berlin, Berlin, Germany; Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt‐Universität zu Berlin, Berlin, Germany; Max‐Delbrück‐Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany; DZHK (German Center for Cardiovascular Research), partner site Berlin, Germany
- 15. Experimental and Clinical Research Center, a cooperation between the Max‐Delbrück‐Center for Molecular Medicine in the Helmholtz Association and the Charité ‐ Universitätsmedizin Berlin, Berlin, Germany; Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt‐Universität zu Berlin, Berlin, Germany; Max‐Delbrück‐Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany; DZHK (German Center for Cardiovascular Research), partner site Berlin, Germany
- 16. Division of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Medical University of Graz, Graz, Austria;
- 17. Department of Obstetrics and Gynaecology, Charité – Universitätsmedizin Berlin, Germany
- 18. Department of Obstetrics and Gynaecology, University Hospital Graz, Medical University Graz, Austria
- 19. Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Division of Obstetrics and Gynaecology, Oslo University Hospital, Norway
- 20. Clinical Biochemistry, King George's Hospital, London, UK
- 21. Fetal Medicine Unit, St George's University Hospitals NHS Foundation Trust, London, UK
- 22. Experimental and Clinical Research Center, a cooperation between the Max‐Delbrück‐Center for Molecular Medicine in the Helmholtz Association and the Charité ‐ Universitätsmedizin Berlin, Berlin, Germany; Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt‐Universität zu Berlin, Berlin, Germany; Max‐Delbrück‐Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany; DZHK (German Center for Cardiovascular Research), partner site Berlin, Germany; HELIOS Clinic, Department of Cardiology and Nephrology, Berlin, Germany
Description
Pre-eclampsia (PE) is a syndrome that affects multiple organ systems and is the most severe hypertensive disorder in pregnancy. It frequently leads to preterm delivery, maternal and fetal morbidity and mortality, and life-long complications (1). We currently lack efficient screening tools (2,3) and early therapies (4,5) to address PE. To study the initial stages of early onset PE and identify candidate markers and pathways, we performed spatio-temporal multi-omics profiling of human PE placentae and healthy controls and validated targets in early gestation in a longitudinal clinical cohort. We used a single-nuclei RNA-seq approach, spatial proteo-, and transcriptomics, and mechanistic in vitro signaling analyses.
This repository contains the single nuclei processed data for decidua and placenta, and Visium (10x spatial transcriptomics) data used in the study. It contains the anndata objects (H5AD) for snRNA-seq with required metadata and NMF-based spot deconvolution data for visium (RDS). The raw Cellranger feature-barcode matrices (H5 files) per donor sample are also included.
References
1 Williams, D. Long-term complications of preeclampsia. Semin Nephrol 31, 111-122,
doi:10.1016/j.semnephrol.2010.10.010 (2011).
2 Brown, M. A. et al. Hypertensive Disorders of Pregnancy: ISSHP Classification,
Diagnosis, and Management Recommendations for International Practice.
Hypertension 72, 24-43, doi:10.1161/HYPERTENSIONAHA.117.10803 (2018).
3 Zeisler, H. et al. Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected
Preeclampsia. N Engl J Med 374, 13-22, doi:10.1056/NEJMoa1414838 (2016).
4 Hauth, J. C. et al. Pregnancy outcomes in healthy nulliparas who developed
hypertension. Calcium for Preeclampsia Prevention Study Group. Obstet Gynecol 95,
24-28, doi:10.1016/s0029-7844(99)00462-7 (2000).
5 Phipps, E. A., Thadhani, R., Benzing, T. & Karumanchi, S. A. Pre-eclampsia:
pathogenesis, novel diagnostics and therapies. Nat Rev Nephrol 15, 275-289,
doi:10.1038/s41581-019-0119-6 (2019).